Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Conversion of Convertible Loan Notes into Equity

3 Jul 2017 07:00

RNS Number : 7635J
Flying Brands Limited
03 July 2017
 

FLYING BRANDS LIMITED

("Flying Brands" or the "Company")

 

Conversion of Convertible Loan Notes into Equity

 

The Company is pleased to announce that Trevor Brown, a director of the Company, has elected to convert £56,000 of his convertible loan notes issued pursuant to a loan note instrument dated 11 March 2015, ("Convertible Loan Notes"), together with accrued interest, into, in aggregate, 5,864,091 ordinary shares of £0.01 each ("Ordinary Shares") at the conversion price of £0.011 per share. Following this conversion, Flying Brands has £213,800 of Convertible Loan Notes outstanding and £100,000 of convertible loan notes issued pursuant to a loan note instrument dated 18 November 2015 outstanding.  

Further details of the Convertible Loan Notes were set out in the Company's announcement and circular, both dated 13 February 2015. 

Following the conversion, the abovementioned 5,864,091 Ordinary Shares will be admitted to trading on the Standard Listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange Main Market for listed securities ("Admission"). Admission will become effective and dealings will commence at 8.00 a.m. on 4 July 2017.  

Following the conversion, Trevor Brown will be directly and indirectly interested in 16,180,788 Ordinary Shares, representing approximately 24.98 per cent. of the Company's enlarged issued ordinary share capital.

Total Voting Rights 

On Admission, the Company will have 64,786,721 Ordinary Shares in issue.

The Company has no Ordinary Shares held in treasury. Accordingly, the above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Corporate Finance (Financial Advisor and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRFBLFXDQFXBBL
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.